Navigation Links
A New Approach In Treatment Neurogenic Detrusor Overactivity In Children

Many reports have dealt with the outcome of botulinum-a toxin (BTX-A) detrusor injections in patients with neurogenic or nonneurogenic detrusor overactivity. BTX-A detrusor injections have been described in adult// patients with neurogenic detrusor overactivity due to spinal cord injury.

Researchers from Germany were able to carry out the same experiments successfully in children with a neurogenic bladder. After many reports of this “wonder drug,” several questions have arisen, including what this injection treatment means for neurourologic patients in the longer term; whether bladder function changes after repeated BTX-A injections, and whether this procedure has a proper place in the treatment algorithm of young patients with neurogenic bladder. In an extension of their previous studies, the authors, set out o assess the long-term success of treatment with repeated botulinum-A toxin (BTX-A; Botox) injections into the detrusor muscle for neurogenic detrusor overactivity in children.

In their study published in the October issue of Urology, the researchers reviewed the charts of 10 children (average age at first injection 11.2 years) with neurogenic detrusor overactivity who had received at least three BTX-A detrusor injections; four had received five or more injections. The total dose of BTX-A was 85 to 300 U. They measured the urodynamic outcomes 6 months after each injection and compared the results after the first injection with the results after the third and fifth injections (in the children who had five or more injections).

The relative changes - each in comparison with the value before injection therapy - after the first versus the fifth injection were as follows: the reflex volume increased by 81% versus 88%, maximal detrusor pressure decreased by 7% versus 39%, maximal cystometric bladder capacity increased by 88% versus 72%, and bladder compliance showed no change at the 6-month follow-up visit after the first injection a nd an increase of 109% after the fifth injection. The results after the third injection were generally similar to those after the fifth injection. No major side effects occurred.

Patients with difficult bladder conditions refractory to anticholinergic drugs have traditionally undergone immediate surgical procedures, such as bladder augmentation. However, according to this new study, BTX-A detrusor injection offers a reliable alternative and protects some of those difficult-to-treat patients for years.
'"/>




Related medicine news :

1. New Dietary Approach To Manage Kidney Stones
2. Approaching through Telemedicine benefits patients
3. Gel Offers A More Targeted Approach
4. New Cost Effective Approach To Promote Sun Protection
5. Treatment Of Brain Aneurysms By A New Non-Surgical Approach
6. A New Diagnostic Approach To Pediatric Interstitial Lung Disease
7. Lazy Eye Can Be Effectively Treated By New Approach
8. Novel Approach to Identify Protein Links with Genetic Disorder
9. NHS To Be Reformed By Using A Hybrid Approach
10. Two-In One Approach To Prevent Incontinence After Prolapse Surgery
11. Women Afflicted With Dry Eyes As They Approach Menopause
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/29/2016)... ... ... On Tuesday, April 26, 2016 members of the HomeTown Health network, a ... Deal on SB 258, the “Rural Health Care Relief” Bill. , The bill, which ... to individuals and corporations which donate directly to a “rural hospital” in Georgia, and ...
(Date:4/29/2016)... ... April 29, 2016 , ... The White House ... their loans, more information about their loan terms and accounts, and more protections ... debt, including federal and private loans, has reached $1.3 trillion, with 43 million ...
(Date:4/29/2016)... ... April 29, 2016 , ... A ... born with severe congenital diaphragmatic hernia have better survival rates if surgery is ... hernia (CDH)—a condition where the diaphragm fails to form completely, letting abdominal organs ...
(Date:4/29/2016)... ... 2016 , ... Mobility Designed is redefining mobility with their patent pending ... Crutch evenly distributes body weight from the elbow to the forearm. In consumer ... than with other crutches. , Co-founders Max and Liliana Younger were inspired to design ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... Melanoma is the deadliest type of skin ... blame for the majority of skin cancer deaths. More than 10,000 people are expected to ... at diagnosis is 62, it is the one of the most commonly diagnosed cancers in ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , April 28, 2016 Oramed Pharmaceuticals ... clinical-stage pharmaceutical company focused on the development of oral drug ... the upcoming PIONEERS 2016 conference, presented by Joseph Gunnar ... in New York . Nadav Kidron ... the conference. Presentation Details:   ...
(Date:4/28/2016)... New market research titled ... report that provides an overview of the Osteoarthritis,s ... identifying new targets and MOAs to produce first-in-class ... in this H1 2016 Osteoarthritis Pipeline report include ... Abiogen Pharma S.p.A., Ablynx NV, Achelios Therapeutics, Inc., ...
(Date:4/27/2016)... , April 27, 2016   ... 42% Growth in Recurring Consumable Sales  Clinical ... Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of ... its sales for the first quarter ended March 31, ... the execution of its commercial strategy. First ...
Breaking Medicine Technology: